2025 Autumn Conference Posters

Click title to view pdf. Posters are listed in numerical order as they appear in the poster session.

1 – Effect of demographics on EEG/ERP biomarkers of schizophrenia: Analysis across four pharma-sponsored CNS clinical trials (Abstract)

Korolev

2 – Impact of rater change in schizophrenia clinical trials using the PANSS (Abstract)

Echevarria

3 – Comparison of percent change from baseline using 10 vs. 30 items of the PANSS in an adult, acutely exacerbated clinical trial population with schizophrenia (Abstract)

Daniel

4 – The prevalence and relationship of anxiety and depression in acute schizophrenia clinical trials (Abstract)

Kott

5 – Methodological considerations and regional differences in risk-based data monitoring in global depression trials (Abstract)

Engler

6 – From paper to precision: Improved MADRS scoring accuracy with eCOA implementation (Abstract)

Rumerman

7 – A composite Rater Performance Index (RPI) to enhance rater oversight in depression clinical trials (Abstract)

Khan

8 – Ensuring data integrity through calibrated central quality reviewers (Abstract)

Roy

9 – COMP 005 and COMP 006: Approaches to challenges in randomized-controlled clinical trials with psychedelics (Abstract)

Hewitt

10 – Precision psychiatry in MDD: Finite mixture modeling of nelivaptan response suggests distinct responder classes (Abstract)

zu Eulenburg

11 – Misclassification of treatment-resistant depression: Addressing trial eligibility by evaluating antidepressant discontinuation (Abstract)

Garneni

12 – Cognitive safety assessment in a randomized, double-blind, phase 2 RSV clinical trial in adults over 60 years of age (Abstract)

Stravoravdi

13 – Cognitive variability as a design consideration in cognitive impairment associated with schizophrenia (CIAS) treatment trials (Abstract)

Harvey

14 – Adapting bridging study methodology for prescription digital therapeutics: A case study in migraine prevention with CT-132 (Abstract)

Snipes

15 – A dual-table framework for rigorous definition of integrated interventions in CNS trials (Abstract)

Price

16 – Combining digital therapeutics with neuroplasticity-inducing agents: A framework modeled on MAT (Abstract)

Murck

17 – Factors influencing adherence in a remote observational study with multiple immunology and neurology disease cohorts (Abstract)

Taptiklis

18 – Do we fully capture patient experiences? Incorporating patient and caregiver voices to define clinical meaningfulness in neurodegenerative trials (Abstract)

Anand

19 – Assessing recruitment funnel performance: A comparative analysis of digital advertising and HCP referrals in Alzheimer’s trials (Abstract)

Belleface

20 – Clustering of medication adherence trajectories (Abstract)

Pironet

21 – Retention unlocked: A tech-enabled operational monitoring and reporting framework to reduce early termination in clinical trials (Abstract)

Gross

22 – AI-enabled direct observation of participant medication adherence predicts early termination risk in clinical trials (Abstract)

Gross

23 – Evaluating the validity of LLM-based psychological assessments: A comparative study using the Attributional Style Questionnaire (Abstract)

Mikus

24 – Leveraging ML-derived patient personas to assess functional unblinding in ketamine trials for major depressive disorder (Abstract)

Geraci

25 – Feasibility of an AI-administered COA using a multi-agent framework (Abstract)

McLaughlin

26 – Benchmarking commercial and open-source speech AI for speaker attribution in real-world clinical conversations (Abstract)

Bruzinski

27 – Maximizing ROI in CNS trials: Using AI models to score 100% of CNS primary outcome interviews and enhance human clinical reviews (Abstract)

DeBonis

28 – Towards more reliable sleep scoring in CNS trials by way of artificial intelligence (Abstract)

Lagler

29 – Challenges of central nervous system (CNS) drug development: Evaluation of European Medicines Agency (EMA) rejections and withdrawals by human and artificial intelligence raters (Abstract)

De Lillo

30 – Using large language models for endpoint oversight (Abstract)

Kolar

32 – A novel method for differentiating acute suicidal ideation and intent using multimodal digital biomarkers (Abstract)

Aafjes

33 – A gamified digital tool for measuring anhedonia and stress reactivity in mood disorders: The losing of control task (Abstract)

Frick

34 – Developing a brain-based metric of depression severity using portable brain measurement (Abstract)

Field

35 – A gamified digital behavioural assessment of core mechanisms underlying depressed mood and anhedonia (Abstract)

Voorn

36 – A digital behavioral assessment of core mechanisms underlying feelings of anxiety and stress in uncertain situations (Abstract)

Bäuerl

37 – Exploring a burst design to improve psychometric properties of a remote digital cognitive assessment for clinical trials in AD (Abstract)

Tröger

38 – Validation of Waveband for evaluation of sleep in hypersomnia disorders (Abstract)

Reh

39 – Developing digital cognitive biomarkers in chronic pain: An augmented reality-based assessment of prospective memory and pain interference (Abstract)

Lutz

40 – Streamlining CNS clinical research with digital endpoints – the trade-off between shorter versus smaller trial designs (Abstract)

Murphy

41 – Interpreting patient- and clinician-reported cognitive measures in schizophrenia (Abstract)

Sommer

42 – Speech markers associated with self- vs. clinician-reported negative symptoms in schizophrenia: Comparing the SNS and PANSS (Abstract)

Menne

43 – Beyond speech: The advantage of combining health information modalities in objective remote assessment of schizophrenia (Abstract)

Gram Sand

44 – An automated integrative pipeline for extracting quantitative, objective speech and language features relevant to mental health (Abstract)

Tang